Document Type : Letter to Editor

Authors

Department of Psychology, Faculty of Literature and Humanities, University of Guilan, Rasht, Iran

Abstract

A type of viral pneumonia that broke out in Wuhan, China in December 2019, and new strains of it are spreading rapidly around the world, is called coronavirus disease 2019 (COVID-19). The incidence of cardiovascular complications has increased both in the general population and in patients diagnosed with the disease during the COVID-19 epidemic. One of the conditions is stress cardiomyopathy, which may be related to COVID-19. During the COVID-19 epidemic, stress cardiomyopathy may be present as a complication of acute infection or as an indirect consequence of quarantine. These conditions have created complications in patient care that have led to increased adverse outcomes, hospitalization, and medical costs. Stress cardiomyopathy is caused by various emotional and physical stressors such as anger, sadness, happiness, surgery, multiple medications, general anesthesia, and infectious diseases. The outbreak of the new coronavirus has posed an ongoing challenge for these patients with several medical and economic consequences. Providing useful information on stress and COVID-19 to people with heart disease and their families can be very important, and also, education and psychotherapy of heart patients can reduce the number of hospitalization and their complications.

Graphical Abstract

Clinical challenges of stress cardiomyopathy during coronavirus 2019 epidemic

Keywords

Main Subjects

Selected author of this article by journal

ِDr. Ebrahim Rahbar Karbasdehi
University of Guilan

Google Scholar

Open Access

This article is licensed under a CC BY License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit: http://creativecommons.org/licenses/by/4.0/

 

Publisher’s Note

CMBR journal remains neutral with regard to jurisdictional claims in published maps and institutional afflictions.

 

Letters to Editor

Given that CMBR Journal's policy in accepting articles will be strict and will do its best to ensure that in addition to having the highest quality published articles, the published articles should have the least similarity (maximum 15%). Also, all the figures and tables in the article must be original and the copyright permission of images must be prepared by authors. However, some articles may have flaws and have passed the journal filter, which dear authors may find fault with. Therefore, the editor of the journal asks the authors, if they see an error in the published articles of the journal, to email the article information along with the documents to the journal office.

CMBR Journal welcomes letters to the editor ([email protected], [email protected]) for the post-publication discussions and corrections which allows debate post publication on its site, through the Letters to Editor. Critical letters can be sent to the journal editor as soon as the article is online. Following points are to be considering before sending the letters (comments) to the editor.

[1] Letters that include statements of statistics, facts, research, or theories should include appropriate references, although more than three are discouraged.

[2] Letters that are personal attacks on an author rather than thoughtful criticism of the author’s ideas will not be considered for publication.

[3] There is no limit to the number of words in a letter.

[4] Letter writers should include a statement at the beginning of the letter stating that it is being submitted either for publication or not.

[5] Anonymous letters will not be considered.

[6] Letter writers must include Name, Email Address, Affiliation, mobile phone number, and Comments.

[7] Letters will be answered as soon as possible.

  1. Velavan TP, Meyer CG (2020) The COVID-19 epidemic. Trop Med Int Health 25(3): 278-280. doi:https://doi.org/10.1111/tmi.13383
  2. Fazeli-Nasab B (2021) Biological Evaluation of Coronaviruses and the Study of Molecular Docking, Linalool, and Thymol as orf1ab Protein Inhibitors and the Role of SARS-CoV-2 Virus in Bioterrorism. journal of ilam university of medical sciences 28(6):77-96. doi:https://doi.org/10.29252/sjimu.28.6.77
  3. Pasqualetto MC, Secco E, Nizzetto M, Scevola M, Altafini L, Cester A, et al. (2020) Stress cardiomyopathy in COVID-19 disease. Eur J Case Rep Intern Med 7(6): 001718. doi:https://doi.org/10.12890/2020_001718
  4. Giustino G, Croft LB, Oates CP, Rahman K, Lerakis S, Reddy VY, et al. (2020) Takotsubo cardiomyopathy in COVID-19. J Am Coll Cardiol 76(5): 628-629. doi:https://doi.org/10.1016/j.jacc.2020.05.068
  5. Shafi AM, Shaikh SA, Shirke MM, Iddawela S, Harky A (2020) Cardiac manifestations in COVID‐19 patients-a systematic review. J Card Surg 35(8): 1988-2008. doi:https://doi.org/10.1111/jocs.14808
  6. Bader F, Manla Y, Atallah B, Starling RC (2021) Heart failure and COVID-19. Heart Fail Rev 26(1): 1-10. doi:https://doi.org/10.1007/s10741-020-10008-2
  7. Salah HM, Mehta JL (2020) Takotsubo cardiomyopathy and COVID-19 infection. Eur Heart J Cardiovasc Imaging 21(11): 1299-1300. doi:https://doi.org/10.1093/ehjci/jeaa236
  8. Sahoo S, Mehra A, Grover S (2021) Stress cardiomyopathy/takotsubo syndrome and COVID-19: An important link to understand. Indian Journal of Clinical Cardiology 2(2): 124-125. doi:https://doi.org/10.1177%2F26324636211000580
  9. Nguyen D, Nguyen T, De Bels D, Castro Rodriguez J (2020) A case of takotsubo cardiomyopathy with COVID 19. Eur Heart J Cardiovasc Imaging 21(9): 1052. doi:https://doi.org/10.1093/ehjci/jeaa152